Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study

Andrew J Wagner, William D Tap, Sebastian Bauer, Jean-Yves Blay, Jayesh Desai, Hans Gelderblom, Emanuela Palmerini, Christopher W Ryan, Charles Peterfy, John H Healey, Michiel van de Sande, Meng Qian, Dale E Shuster, Abdul Rajper, Xin Ye, Kristen Tecson, Margaret J Wooddell, Silvia Stacchiotti

Open source

DOI: 10.1093/oncolo/oyae345
Published: 2025-07
Container: The Oncologist
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyae345,
  title = {Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study},
  author = {Andrew J Wagner and William D Tap and Sebastian Bauer and Jean-Yves Blay and Jayesh Desai and Hans Gelderblom and Emanuela Palmerini and Christopher W Ryan and Charles Peterfy and John H Healey and Michiel van de Sande and Meng Qian and Dale E Shuster and Abdul Rajper and Xin Ye and Kristen Tecson and Margaret J Wooddell and Silvia Stacchiotti},
  year = {2025},
  journal = {The Oncologist},
  doi = {10.1093/oncolo/oyae345},
  url = {https://doi.org/10.1093/oncolo/oyae345}
}

RIS

TY  - JOUR
TI  - Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study
AU  - Andrew J Wagner
AU  - William D Tap
AU  - Sebastian Bauer
AU  - Jean-Yves Blay
AU  - Jayesh Desai
AU  - Hans Gelderblom
AU  - Emanuela Palmerini
AU  - Christopher W Ryan
AU  - Charles Peterfy
AU  - John H Healey
AU  - Michiel van de Sande
AU  - Meng Qian
AU  - Dale E Shuster
AU  - Abdul Rajper
AU  - Xin Ye
AU  - Kristen Tecson
AU  - Margaret J Wooddell
AU  - Silvia Stacchiotti
PY  - 2025
JO  - The Oncologist
DO  - 10.1093/oncolo/oyae345
UR  - https://doi.org/10.1093/oncolo/oyae345
ER  -

APA

Wagner, A. J., Tap, W. D., Bauer, S., Blay, J., Desai, J., Gelderblom, H., Palmerini, E., Ryan, C. W., Peterfy, C., Healey, J. H., Sande, M. V. D., Qian, M., Shuster, D. E., Rajper, A., Ye, X., Tecson, K., Wooddell, M. J., & Stacchiotti, S. (2025). Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study. The Oncologist. https://doi.org/10.1093/oncolo/oyae345

Source records

crossref · retrieved 2026-09-27T03:06:07.140Z